Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
about
Positron Emission Tomography in Breast CancerNovel therapeutic strategies for patients with triple-negative breast cancerDo clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCISTStratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.Predictive Ability of 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients.Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging.Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer.[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
P2860
Q26768486-FC9E4552-BDFD-4D5B-B19C-2F9061309A8BQ28067436-C8761B9C-C5C5-423A-8710-29B89559B075Q33576007-9306927D-5231-44A0-AE1F-EFF850ABEC9CQ33860281-DDFC2B10-13ED-4477-A256-CD5AE77C439AQ36109265-148B3820-8B5D-4B3A-950D-DD61EF924CB8Q37077266-5ACB56E0-007D-4CB4-A31F-E95C03C38512Q40219495-EC9FD5FD-CA91-43E3-ABBD-E2A36F7CE998Q42479479-FE4CEB86-F6B9-48E4-8F4E-FD1891017232Q47856252-FA07979B-CEBA-438B-90D7-9AA5D420B22BQ50100711-B18F5149-DA69-438F-987D-DD1F4ED703B8Q53396296-BBCACD4B-6AED-4C13-B9B7-36E488418A04Q55286904-A8C39DB2-E1FF-4E00-A6B8-CE58231DD264
P2860
Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Prognostic impact of 18F-FDG P ...... triple-negative breast cancer.
@en
Prognostic impact of 18F-FDG P ...... triple-negative breast cancer.
@nl
type
label
Prognostic impact of 18F-FDG P ...... triple-negative breast cancer.
@en
Prognostic impact of 18F-FDG P ...... triple-negative breast cancer.
@nl
prefLabel
Prognostic impact of 18F-FDG P ...... triple-negative breast cancer.
@en
Prognostic impact of 18F-FDG P ...... triple-negative breast cancer.
@nl
P2093
P2860
P1476
Prognostic impact of 18F-FDG P ...... triple-negative breast cancer
@en
P2093
A de Roquancourt
S Giacchetti
P2860
P2888
P304
P356
10.1007/S00259-014-2941-1
P577
2014-11-29T00:00:00Z